Cargando…

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells

Programmed cell death ligand 1 (PD-L1) is a transmembrane protein that is expressed on tumor cells that suppresses the T cell-mediated immune response. Therapies targeting the PD-L1 pathway promote anti-tumor immunity and have shown promising results in some types of cancers. However, the functional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Yunfei, Chen, Lulu, Feng, Yong, Shen, Jacson, Gao, Yan, Cote, Gregory, Choy, Edwin, Harmon, David, Mankin, Henry, Hornicek, Francis, Duan, Zhenfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444742/ https://www.ncbi.nlm.nih.gov/pubmed/28415820 http://dx.doi.org/10.18632/oncotarget.16326

Ejemplares similares

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
por: Feng, Yong, et al.
Publicado: (2015)

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
por: Duan, Zhenfeng, et al.
Publicado: (2014)

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2017)

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2018)

miR‐15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo
por: Duan, Zhenfeng, et al.
Publicado: (2016)

CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma
por: Gao, Yan, et al.
Publicado: (2015)

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro
por: Shen, Jacson K., et al.
Publicado: (2016)

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010)

Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats
por: Gao, Yan, et al.
Publicado: (2016)

Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance
por: Liu, Tang, et al.
Publicado: (2016)

Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

ZNF93 Increases Resistance to ET-743 (Trabectedin; Yondelis®) and PM00104 (Zalypsis®) in Human Cancer Cell Lines
por: Duan, Zhenfeng, et al.
Publicado: (2009)

Correction to: Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells
por: Chen, Hua, et al.
Publicado: (2017)

Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma
por: Susa, Michiro, et al.
Publicado: (2010)

Rhabdomyosarcoma: Advances in Molecular and Cellular Biology
por: Sun, Xin, et al.
Publicado: (2015)

MicroRNA-155 expression is independently predictive of outcome in chordoma
por: Osaka, Eiji, et al.
Publicado: (2015)

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)

NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance
por: Duan, Zhenfeng, et al.
Publicado: (2009)

Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma
por: Susa, Michiro, et al.
Publicado: (2009)

Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
por: Sun, Ranran, et al.
Publicado: (2016)

Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells
por: Zhang, Linlin, et al.
Publicado: (2015)

MicroRNA Involvement in Osteosarcoma
por: Kobayashi, Eisuke, et al.
Publicado: (2012)

Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma
por: Guo, Shang, et al.
Publicado: (2014)

Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer
por: Gao, Yan, et al.
Publicado: (2015)

Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma
por: Zhang, Linlin, et al.
Publicado: (2013)

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
por: Zhou, Yubing, et al.
Publicado: (2016)

Noncoding RNA in drug resistant sarcoma
por: Li, Xiaoyang, et al.
Publicado: (2017)

Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma
por: Liu, Pei, et al.
Publicado: (2017)

The role of extracelluar matrix in osteosarcoma progression and metastasis
por: Cui, Juncheng, et al.
Publicado: (2020)

Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1
por: Choy, Edwin, et al.
Publicado: (2014)

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2018)

SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
por: Guo, Tao, et al.
Publicado: (2022)

Expression and Clinical Significance of High‐Mobility Group AT‐hook 2 (HMGA2) in Osteosarcoma
por: Cui, Juncheng, et al.
Publicado: (2022)

Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma
por: Li, Xiaoyang, et al.
Publicado: (2020)

Extraskeletal osteosarcoma: A large series treated at a single institution
por: Wang, Haotong, et al.
Publicado: (2018)

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Thanindratarn, Pichaya, et al.
Publicado: (2021)

Development of a new pre-vascularized tissue-engineered construct using pre-differentiated rADSCs, arteriovenous vascular bundle and porous nano-hydroxyapatide-polyamide 66 scaffold
por: Yang, Pei, et al.
Publicado: (2013)

Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma
por: Feng, Wenlong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1fu45t1psk6aq7veut55ktou3h